z-logo
open-access-imgOpen Access
Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant Phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer
Author(s) -
Aranzazu Fernández-Martínez,
I.E. Krop,
D.W. Hillman,
M.-Y. Polley,
J.S. Parker,
L. Huebner,
K.A. Hoadley,
J. Shepherd,
S. Tolaney,
N. Lynn Henry,
C. Dang,
L. Harris,
D. Berry,
O. Hahn,
C. Hudis,
E. Winer,
A. Partridge,
C.M Perou,
L.A. Carey
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/5xyh-n336
Subject(s) - trastuzumab , lapatinib , paclitaxel , medicine , oncology , breast cancer , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom